文献速递白血病

CALGB 10603/RATIFY试验中FLT3突变急性髓系白血病患者的基因组图谱

Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
PubMed 文献 · Leukemia · 2022-08-03

本研究对CALGB 10603/RATIFY随机试验中475例FLT3突变急性髓系白血病患者进行262个基因测序,评估强化化疗联合米哚妥林与安慰剂对比。发现NPM1(61%)、DNMT3A(39%)等共突变常见,WT1和NPM1突变预后影响最大,NPM1突变可抵消WT1突变的负面效应,米哚妥林对WT1突变AML有获益。

要点

  • FLT3突变AML常见共突变为NPM1(61%)、DNMT3A(39%)、WT1(21%)。
  • 预后影响最大为WT1和NPM1突变,其次为白细胞计数、FLT3突变类型等。
  • NPM1突变可抵消WT1突变的负面效应,米哚妥林对WT1突变AML有获益。

核心结论

  • 该靶向基因测序研究为FLT3突变AML的基因组背景提供了重要新见解,包括共突变的预后影响、特定基因-基因相互作用以及米哚妥林可能的治疗效果。

研究设计与样本

  • 研究基于随机CALGB 10603/RATIFY试验,纳入475例FLT3突变AML患者,对262个基因进行测序,比较强化化疗联合多激酶抑制剂米哚妥林与安慰剂。

主要发现

  • 与FLT3突变同时发生的突变最常见于NPM1(61%)、DNMT3A(39%)、WT1(21%)、TET2(12%)、NRAS(11%)、RUNX1(11%)、PTPN11(10%)和ASXL1(8%)基因。
  • 预后影响最大的是WT1和NPM1突变,其次是白细胞计数、FLT3突变类型(内部串联重复 vs 酪氨酸激酶结构域突变)、治疗(米哚妥林 vs 安慰剂)、ASXL1突变和ECOG体能状态。
  • 评估两倍变量组合时,最显著的效果见于WT1:NPM1(NPM1突变抵消WT1突变的负面效应)和WT1:治疗(米哚妥林对WT1突变AML发挥有益效应)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this study was to characterize the mutational landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the randomized CALGB 10603/RATIFY trial evaluating intensive chemotherapy plus the multi-kinase inhibitor midostaurin versus placebo. We performed sequencing of 262 genes in 475 patients: mutations occurring concurrently with the FLT3-mutation were most frequent in NPM1 (61%), DNMT3A (39%), WT1 (21%), TET2 (12%), NRAS (11%), RUNX1 (11%), PTPN11 (10%), and ASXL1 (8%) genes. To assess effects of clinical and genetic features and their possible interactions, we fitted random survival forests and interpreted the resulting variable importance. Highest prognostic impact was found for WT1 and NPM1 mutations, followed by white blood cell count, FLT3 mutation type (internal tandem duplications vs. tyrosine kinase domain mutations), treatment (midostaurin vs. placebo), ASXL1 mutation, and ECOG performance status. When evaluating two-fold variable combinations the most striking effects were found for WT1:NPM1 (with NPM1 mutation abrogating the negative effect of WT1 mutation), and for WT1:treatment (with midostaurin exerting a beneficial effect in WT1-mutated AML). This targeted gene sequencing study provides important, novel insights into the genomic background of FLT3-mutated AML including the prognostic impact of co-mutations, specific gene-gene interactions, and possible treatment effects of midostaurin.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Jahn N, Jahn E, Saadati M, et al. Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial. Leukemia. 2022. PMID: 35922444. doi:10.1038/s41375-022-01650-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。